Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire•05/10/2026•16:02 ET
1
Key Highlights
- ➤Verastem grants 380,500 RSUs to 24 new employees
- ➤Verastem grants options for 50,000 shares to one new employee
- ➤Stock options carry a $7.90 exercise price
- ➤Awards vest 25% after one year, then quarterly over three years
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 380,500 restricted stock units (RSUs) to 24 new employees and stock options to purchase 50,000 shares of its common stock to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee’s acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4).
Get started
Create a free account to read the full story.